A recent study [56] showed that PRKDC mutation was significantly associated with a high mutation load or high-MSI status in cancer on the basis of the TCGA pan-cancer cohort and, more importantly, PRKDC knockout and DNA-PKcs inhibitor enhanced the efficacy of immunological checkpoint inhibitors (ICI). This evidence concerns the gene PRKDC and cancer.